10 completed, 1 enrolling by invitation, 1 recruiting, 1 suspended. 14 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 14 | Completed 10, Enrolling by invitation 1, Recruiting 1, Suspended 1, Terminated 1 |
Follow Quinapril: new trials by email Literature Review of Quinapril trials Research Report on Quinapril
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD) Finerenone, Semaglutide, Lotensin - Chronic Kidney Disease, Type 2 Diabetes | Phase 4 | Enrolling by invitation | Baylor Research Institute | 64 | 2026-04-08 | 2026-10-13 |
| Coronavirus (COVID-19) ACEi/ARB Investigation Thiazide or Thiazide-like diuretics, Calcium Channel Blockers, ACE inhibitor - Hypertension, COVID-19 | Phase 4 | Suspended | National University of Ireland, Galway, Ireland | 2414 | 2020-04-30 | 2020-06-30 |
| Diabetic Autonomic Neuropathy and Left Ventricular Function Quinapril, Losartan, Quinapril + Losartan - Diabetes Mellitus | Phase 4 | Completed | AHEPA University Hospital | 59 | 2017-01-01 | 2023-02-06 |
| NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients RAS-antagonist and beta-blocker up-to maximal dosages, RAS-antagonist and beta-blocker none or at stable dose - Heart Diseases, Diabetes Mellitus, Type 2 | Phase 4 | Recruiting | Martin Huelsmann | 2400 | 2016-02-01 | 2023-03-14 |
| Chronic Angiotensin Converting Enzyme Inhibitors in Intermediate Risk Surgery ACEI continuation, ACEI omission - Hypotension on Induction | Phase 4 | Completed | University of Nebraska | 291 | 2015-06-01 | 2023-09-25 |
| Atrial Substrate Modification With Aggressive Blood Pressure Lowering to Prevent AF Aggressive Blood Pressure control - Atrial Fibrillation | Phase 4 | Completed | Nova Scotia Health Authority | 184 | 2009-12-01 | 2017-06-20 |
| Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment Any antihypertensive medication alone or in combination, Ambulatory blood pressure monitoring - Essential Hypertension, Cardiovascular Disease | Phase 4 | Completed | University of Vigo | 21983 | 2008-09-01 | 2018-08-28 |
| High-Dose Quinapril Versus Low-Dose Quinapril Plus Amlodipine in the Treatment of High-Risk Hypertensive Patients Quinapril 40 mg, Quinapril 10 mg and amlodipine 5 mg - Hypertension | Phase 4 | Terminated | Montreal Heart Institute | 40 | 2006-04-01 | 2008-05-06 |
| Non-Comparative Study To Evaluate Changes In FMD After Quinapril Therapy In Hypertensive Women quinapril, Laser Doppler imaging - Menopause, Hypertension | Phase 4 | Completed | Pfizer | 70 | 2003-10-01 | 2007-04-30 |
| A Study to Evaluate the Efficacy and Safety of Quinapril or Quinapril Plus Hydrochlorothiazide in Patients With Mild to Moderate Hypertension quinapril 20 mg, quinapril 20 mg plus hydrochlorothiazide 12.5 mg, quinapril 40 mg - Hypertension | Phase 4 | Completed | Pfizer | 200 | 2002-12-01 | 2008-04-10 |
| QWISE - Study of Quinapril in Women With Chest Pain, Coronary Flow Reserve Limitations and Evidence of Myocardial Ischemia Quinapril, Placebo - Ischemic Heart Disease | Phase 4 | Completed | University of Florida | 78 | 2000-05-01 | 2012-04-13 |
| Ambulatory Blood Pressure Monitoring in the Prediction of Cardiovascular Events and Effects of Chronotherapy Ambulatory blood pressure monitoring, Chronotherapy, timing of antihypertensive medication, ACEI (including spirapril, enalapril, quinapril, lisinopril) - Hypertension | Phase 4 | Completed | University of Vigo | 3344 | 2000-03-01 | 2009-04-28 |
| Management With Accupril Post Bypass Graft Quinapril - CABG | Phase 4 | Completed | Montreal Heart Institute | 1999-11-01 | 2006-02-08 | |
| Efficacy of Administration of ACE-Inhibition on Autonomic and Peripheral Neuropathy in Patients With Diabetes Mellitus Quinapril - Diabetic Autonomic Neuropathy | Phase 4 | Completed | Aristotle University Of Thessaloniki | 1999-01-01 | 2017-01-26 |
Hypertension (5) · Diabetes Mellitus, Type 2 (3) · Cardiovascular Diseases (2) · Renal Insufficiency, Chronic (2) · Albuminuria (1) · Atrial Fibrillation (1) · COVID-19 (1) · Coronavirus Infections (1) · Diabetes Mellitus (1) · Diabetic Neuropathies (1) · Essential Hypertension (1) · Heart Diseases (1) · Hyperkalemia (1) · Myocardial Ischemia (1) · Stroke (1)
Montreal Heart Institute (2) · Pfizer (2) · University of Vigo (2) · AHEPA University Hospital (1) · Aristotle University Of Thessaloniki (1) · Baylor Research Institute (1) · Martin Huelsmann (1) · National University of Ireland, Galway, Ireland (1) · Nova Scotia Health Authority (1) · University of Florida (1) · University of Nebraska (1)
Spain (3) · United States (3) · Canada (2) · Austria (1) · Greece (1) · Hungary (1) · Ireland (1) · Netherlands (1) · New Zealand (1) · Turkey (Türkiye) (1) · United Kingdom (1)
Ramon C Hermida, PhD (2) · Carl J Pepine, MD (1) · Jacques de Champlain, MD, PhD (1) · Jason F Shiffermiller, MD, MPH (1) · Jean-Lucien Rouleau, M.D (1) · John William McEvoy, MBBCh MHS (1) · Martin Huelsmann, Doz.Dr. (1) · Michel White, MD (1) · Ratika Parkash, MD MSc (1) · Simon de Denus, B. Pharm, MSc (1) · Triantafillos Didangelos, Professor (1)
PMID 19407805, PMID 21617110, PMID 21884956, PMID 21982660, PMID 26399404, PMID 27221952, PMID 28228428, PMID 30261084, PMID 31641769, PMID 34530738
U01HL064924 (1)